Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rebus Biosystems

Explore full profile

A venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise

Santa Clara, United StatesFounded 2006Health Tech & Medtech
Valuation $100–250M Last recorded · 2022
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Rebus Biosystems and the history behind them.

About Rebus Biosystems

Rebus Biosystems is a Silicon Valley-based life science technology company that specializes in creating advanced tools for spatial omics research. The company's flagship product, the Rebus Esper, is an automated, fully integrated spatial omics platform that provides high-resolution, quantitative single molecule data while maintaining the spatial context of cells. This technology is particularly valuable for researchers studying complex biological systems, such as brain development, by enabling them to obtain high-sensitivity data from hundreds of thousands of cells in a single experiment. Rebus Biosystems primarily serves academic and industrial researchers in the life sciences sector who require precise and comprehensive data for their studies. The company operates in the rapidly growing market of spatial omics, which combines spatial information with molecular data to provide a more detailed understanding of biological processes. Rebus Biosystems generates revenue through the sale of its Rebus Esper platform and associated consumables, as well as through service contracts and support agreements. The business model focuses on providing a streamlined, end-to-end solution that minimizes hands-on time for users, making advanced spatial omics research more accessible and efficient.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2006
Headquarters
Santa Clara, United States
Employees
8
Open positions
None listed
Dealroom signal
28.7/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Biotechnology, Biotech and Pharma, Techbio, CompBio, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Nov 2022 $32M $129M Undisclosed ↗
SERIES BOther financing Nov 2020 $20M $80M NCore Ventures · Labgenomics · Timefolio Asset Management · Illumina Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rebus Biosystems website traffic

Latest recorded traffic for Rebus Biosystems is 180 monthly website visits, down 79.3% over the last three months. Rebus Biosystems's team grew 0% over the past year.

Latest monthly visits180 3-month web change-79.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Illumina Ventures
  • NCore Ventures
  • Labgenomics
  • Timefolio Asset Management
  • Seegene
  • Xolon Invest
  • CTK Investments
  • Ray Medical
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rebus Biosystems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rebus Biosystems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.